JP7814090B2 - ワクチンアジュバントとしての間葉系幹細胞及びそれを使用するための方法 - Google Patents

ワクチンアジュバントとしての間葉系幹細胞及びそれを使用するための方法

Info

Publication number
JP7814090B2
JP7814090B2 JP2018541195A JP2018541195A JP7814090B2 JP 7814090 B2 JP7814090 B2 JP 7814090B2 JP 2018541195 A JP2018541195 A JP 2018541195A JP 2018541195 A JP2018541195 A JP 2018541195A JP 7814090 B2 JP7814090 B2 JP 7814090B2
Authority
JP
Japan
Prior art keywords
vaccine
adjuvant
mesenchymal stem
stem cells
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018541195A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509264A (ja
JP2019509264A5 (https=
Inventor
ジョシュア エム． ハレ，
アナ マリー ランディン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Longeveron Inc
Original Assignee
Longeveron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Longeveron Inc filed Critical Longeveron Inc
Publication of JP2019509264A publication Critical patent/JP2019509264A/ja
Publication of JP2019509264A5 publication Critical patent/JP2019509264A5/ja
Priority to JP2023000567A priority Critical patent/JP2023036949A/ja
Priority to JP2025173389A priority patent/JP2026012755A/ja
Application granted granted Critical
Publication of JP7814090B2 publication Critical patent/JP7814090B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018541195A 2016-02-04 2017-02-02 ワクチンアジュバントとしての間葉系幹細胞及びそれを使用するための方法 Active JP7814090B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023000567A JP2023036949A (ja) 2016-02-04 2023-01-05 ワクチンアジュバントとしての間葉系幹細胞及びそれを使用するための方法
JP2025173389A JP2026012755A (ja) 2016-02-04 2025-10-15 ワクチンアジュバントとしての間葉系幹細胞及びそれを使用するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291350P 2016-02-04 2016-02-04
US62/291,350 2016-02-04
PCT/US2017/016200 WO2017136539A1 (en) 2016-02-04 2017-02-02 Mesenchymal stem cells as vaccine adjuvants and methods for using the same

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2023000567A Division JP2023036949A (ja) 2016-02-04 2023-01-05 ワクチンアジュバントとしての間葉系幹細胞及びそれを使用するための方法
JP2025173389A Division JP2026012755A (ja) 2016-02-04 2025-10-15 ワクチンアジュバントとしての間葉系幹細胞及びそれを使用するための方法

Publications (3)

Publication Number Publication Date
JP2019509264A JP2019509264A (ja) 2019-04-04
JP2019509264A5 JP2019509264A5 (https=) 2020-03-12
JP7814090B2 true JP7814090B2 (ja) 2026-02-16

Family

ID=58261704

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018541195A Active JP7814090B2 (ja) 2016-02-04 2017-02-02 ワクチンアジュバントとしての間葉系幹細胞及びそれを使用するための方法
JP2023000567A Pending JP2023036949A (ja) 2016-02-04 2023-01-05 ワクチンアジュバントとしての間葉系幹細胞及びそれを使用するための方法
JP2025173389A Pending JP2026012755A (ja) 2016-02-04 2025-10-15 ワクチンアジュバントとしての間葉系幹細胞及びそれを使用するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023000567A Pending JP2023036949A (ja) 2016-02-04 2023-01-05 ワクチンアジュバントとしての間葉系幹細胞及びそれを使用するための方法
JP2025173389A Pending JP2026012755A (ja) 2016-02-04 2025-10-15 ワクチンアジュバントとしての間葉系幹細胞及びそれを使用するための方法

Country Status (11)

Country Link
US (2) US11975068B2 (https=)
EP (2) EP4316497A3 (https=)
JP (3) JP7814090B2 (https=)
KR (1) KR20180105705A (https=)
AU (2) AU2017213812B2 (https=)
CA (1) CA3013457A1 (https=)
ES (1) ES2960206T3 (https=)
IL (1) IL260858B (https=)
SG (1) SG11201806587RA (https=)
WO (1) WO2017136539A1 (https=)
ZA (2) ZA201805159B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020166063A1 (ja) * 2019-02-15 2020-08-20 大和薬品株式会社 フレイル改善方法およびフレイル改善食品
CN111568927A (zh) * 2020-05-23 2020-08-25 湖南源品细胞生物科技有限公司 一种msc用于调节记忆b细胞数量的应用
JP2023540096A (ja) 2020-09-08 2023-09-21 ロングエバーオン インコーポレイテッド アロジェニック間葉系幹細胞によるアルツハイマー病の治療
CN112641938A (zh) * 2020-11-22 2021-04-13 翁炳焕 一种dna重组干细胞载体新冠疫苗
US20220218817A1 (en) * 2021-01-08 2022-07-14 Vitro Biopharma, Inc. Immune modulation by mesenchymal stem cells
CN117999082A (zh) 2021-07-26 2024-05-07 美商生命科学有限公司 间充质干细胞在治疗青少年左心发育不良综合征中的用途
WO2025137077A1 (en) 2023-12-19 2025-06-26 Longeveron, Inc. Improved brain architecture and biomarkers in alzheimer's disease with mesenchymal stem cells
WO2025199451A2 (en) 2024-03-21 2025-09-25 Longeveron Inc. Mmp-14 potency assay for mesenchymal stem cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2999199A (en) 1998-04-03 1999-10-25 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
US8554280B2 (en) 2010-03-23 2013-10-08 Ebay Inc. Free-form entries during payment processes
US10472647B2 (en) 2012-12-21 2019-11-12 The Administrators Of The Tulane Educational Fund Primary mesenchymal stem cells as a vaccine platform
WO2014100857A1 (en) 2012-12-24 2014-07-03 Cell Ideas Pty Ltd Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
US9101597B2 (en) 2013-03-14 2015-08-11 The Administration Of The Tulane Educational Fund Immunoprotective primary mesenchymal stem cells and methods
CN104138391B (zh) 2013-05-08 2018-07-31 中国科学院上海生命科学研究院 间充质干细胞在预防或治疗应激反应导致的免疫力下降中的应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ASO, K. et al., Adipose-Derived Mesenchymal Stem Cells Restore Impaired Mucosal Immune Responses in Aged Mice, PLoS ONE, 2016年02月03日, Vol. 11, No. 2, e0148185
Immunol. Res., 2013年, Vol. 57, pp. 354-360
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2015年11月19日, Vol. 37, pp. 115-125
免疫学辞典（第２版）, 日本, 2001年, p. 12, 597

Also Published As

Publication number Publication date
CA3013457A1 (en) 2017-08-10
JP2026012755A (ja) 2026-01-27
JP2023036949A (ja) 2023-03-14
EP3411050B1 (en) 2023-09-27
WO2017136539A1 (en) 2017-08-10
AU2017213812B2 (en) 2024-04-04
SG11201806587RA (en) 2018-09-27
EP4316497A2 (en) 2024-02-07
JP2019509264A (ja) 2019-04-04
ES2960206T3 (es) 2024-03-01
US20190038742A1 (en) 2019-02-07
AU2024204598A1 (en) 2024-07-18
ZA202000574B (en) 2021-08-25
EP3411050A1 (en) 2018-12-12
ZA201805159B (en) 2020-10-28
EP4316497A3 (en) 2024-05-01
US11975068B2 (en) 2024-05-07
IL260858B (en) 2022-04-01
AU2017213812A1 (en) 2018-08-16
IL260858A (en) 2018-10-31
US20240252627A1 (en) 2024-08-01
KR20180105705A (ko) 2018-09-28

Similar Documents

Publication Publication Date Title
JP7814090B2 (ja) ワクチンアジュバントとしての間葉系幹細胞及びそれを使用するための方法
Jabbari et al. Secondary memory CD8+ T cells are more protective but slower to acquire a central–memory phenotype
TWI820753B (zh) 使用人類間葉幹細胞以實現細胞性及體液性免疫的方法
KR101788885B1 (ko) 세포 요법에 사용하기 위한 방법 및 조성물
Jobe et al. Immunization with radiation-attenuated Plasmodium berghei sporozoites induces liver cCD8α+ DC that activate CD8+ T cells against liver-stage malaria
Hwang et al. Distinct CD 4 T‐cell effects on primary versus recall CD 8 T‐cell responses during viral encephalomyelitis
ES2987001T3 (es) Tratamiento de la caquexia usando células de fibroblasto y productos de las mismas
Ivanova et al. Anti-Asialo GM1 treatment during secondary Toxoplasma gondii infection is lethal and depletes T cells
HK40109512A (zh) 使用人类间充质干细胞以实现细胞免疫及体液免疫的方法
Russell Inducing IL-1β to increase vaccine efficacy
Habiela The Role of Follicular Dendritic Cells and Persisting Foot-And-Mouth Disease Virus Antigens as Determinants of Immune Responses to the Virus
US20210171581A1 (en) Immune activation triggered by filovirus proteins and polypeptides
JP2008536511A (ja) ＣＤ８Ｔ細胞の活性化方法｛ＭｅｔｈｏｄＦｏｒＡｃｔｉｖａｔｉｎｇＣＤ８ＴＣｅｌｌｓ｝
Gasper Cell-Mediated Antiviral Immunity And Host Responses to CD8 T-cell Vaccines and Respiratory Virus Infection
Ng Loss and Recovery of Humoral Immunity to Influenza Virus Following Malaria Infection
McEwen-Smith An investigation into the regulatory capacity of invariant natural killer T (iNKT) cells during the innate and adaptive immune response to influenza infection
Liu CD8+ T cell response to lymphocytic choriomeningitis virus infection
Edwards Programming protective CD4-independent CD8 T cell memory

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190918

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20200203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210330

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220408

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230105

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230105

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230117

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230224

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230228

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260203

R150 Certificate of patent or registration of utility model

Ref document number: 7814090

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150